AUAkinori Uruha

Akinori Uruha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akinori Uruha has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Ichizo Nishino

    Department of Neuromuscular Research National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) Tokyo Japan

    6 shared publications
  • Ichizo Nishino

    Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

    4 shared publications
  • Shigeaki Suzuki

    Shigeaki Suzuki, MD, PhD, Department of Neurology, Keio University School of Medicine, Tokyo, Japan

    4 shared publications
  • Shigeaki Suzuki

    Department of Neurology, Tokyo Metropolitan Neurological Hospital

    4 shared publications
  • Munenori Oyama

    3 shared publications
  • Jantima Tanboon

    Affiliation Department of Neuromuscular Research, National Institute of Neuroscience, and Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan

    2 shared publications

Latest Publications

  • Clinical and Pathological Research on Myositis

    by Akinori Uruha

    Idiopathic inflammatory myopathy, or autoimmune myositis, has traditionally been classified as polymyositis and dermatomyositis; however, advances in serological and pathological analyses have revealed the limitations of this framework. Currently, the major subtypes of autoimmune myositis include dermatomyositis, antisynthetase syndrome, immune‐mediated necrotizing myopathy, and inclusion body myositis. This review summarizes recent advances in understanding the clinical and pathological features and pathomechanisms of each autoimmune myositis subtype, which serve as the basis for modern classification. We identified the expression of myxovirus resistance protein A, a Type I interferon‐induced protein, in the sarcoplasm as a novel pathological marker of dermatomyositis, improving diagnostic sensitivity. Although some symptoms overlap between dermatomyositis and antisynthetase syndrome, these two conditions are distinct in their pathological characteristics. Antisynthetase syndrome‐associated myositis is characterized pathologically by perifascicular necrosis, in contrast to the perifascicular atrophy seen in dermatomyositis. Moreover, an immunological micro‐milieu favorable to plasma cell survival is specifically present in the skeletal muscle of antisynthetase syndrome. Immune‐mediated necrotizing myopathy is pathologically defined by a prominent necrotic and regenerating process. Importantly, some pediatric and young adult cases resemble muscular dystrophy, potentially leading to delays in diagnosis and treatment. High serum creatine kinase levels exceeding 1000 U/L, a clinical diagnosis of “muscular dystrophy” without genetic confirmation, and onset during normal motor development are red flags for this disease. Inclusion body myositis is characterized by both inflammatory and degenerative features and may represent a disease spectrum that includes an earlier stage, polymyositis with mitochondrial pathology.

  • Myositis associated with antimitochondrial autoantibodies presenting with early respiratory failure

    by Kentaro Kawama, Shinsuke Tobisawa, Akinori Uruha, Satoko Uruha, Hirotake Nishimura, Hiromi Onizuka, Kenta Masui, Saeko Yoshizawa, Tomoko Yamamoto, Takashi Komori, et al.


  • Update on pathology of inflammatory myopathy

    by Akinori Uruha, Satoko Uruha

    Inflammatory myopathy is classified into primary autoimmune myositis and secondary myositis due to various factors, such as drugs and autoimmune connective tissue diseases. Autoimmune myositis mainly consists of dermatomyositis, antisynthetase syndrome‐associated myositis, immune‐mediated necrotizing myopathy, and inclusion body myositis. This review aims to provide insights into muscle pathology for clinical practice and an understanding of pathophysiology in inflammatory myopathy by summarizing current knowledge about the pathology of each subform of autoimmune myositis and some secondary myositis. Dermatomyositis is associated with type I interferon upregulation. Expression of myxovirus resistance protein A (a type I interferon‐induced protein) in myofibers is utilized as a sensitive diagnostic marker. Antisynthetase syndrome‐associated myositis is morphologically characterized by perifascicular necrosis. A recent study suggests the presence of a characteristic immunological micromilieu suitable for plasma cells in the skeletal muscle tissue. Immune‐mediated necrotizing myopathy features an active necrotic and regenerating process. In inclusion body myositis, inflammatory cellular infiltration and rimmed vacuoles reflecting autophagy disruption are observed. The lymphocytes invading myofibers are composed of a highly differentiated T‐cell population, which is considered a potential therapeutic target.


  • Pathologic Features of Anti-Ku Myositis

    by Munenori Oyama, Marie-Therese Holzer, Yuko Ohnuki, Yoshihiko Saito, Yukako Nishimori, Takashi Shiina, Sarah Leonard-Louis, Olivier Benveniste, Udo Schneider, Werner Stenzel, et al.

    Characteristics of myositis with anti-Ku antibodies are poorly understood. The purpose of this study was to elucidate the pathologic features of myositis associated with anti-Ku antibodies, compared with immune-mediated necrotizing myopathy (IMNM) with anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies, in muscle biopsy-oriented registration cohorts in Japan and Germany. We performed a retrospective pathology review of patients with anti-Ku myositis samples diagnosed in the Japanese and German cohorts. We evaluated histologic features and performed HLA phenotyping. Fifty biopsied muscle samples in the Japanese cohort and 10 in the German cohort were obtained. After exclusion of myositis-specific autoantibodies or other autoimmune connective tissue diseases, 26 samples (43%) of anti-Ku antibody-positive myositis were analyzed. All the samples shared some common features with IMNM, whereas they showed expression of MHC class II and clusters of perivascular inflammatory cells more frequently than the anti-SRP/HMGCR IMNM samples (71% vs 7%/16%; p < 0.005/p < 0.005/p = 0.0045, 0.019, and 0.027; odds ratio [OR] 50.2, 4.6, and 2.8; 95% CI 2.6-2942.1, 1.1-14.5, and 1.0-7.0) in the group with less conspicuous necrosis and regeneration. On the contrary, in the group of more abundant necrosis and regeneration, the allele frequencies of HLA-A*24:02, HLA-B*52:01, HLA-C*12:02, and HLA-DRB1*15:02 were lower than those of healthy controls (p = 0.0036, 0.027, 0.016, and 0.026; OR = 0.27, 0, 0, and 0; 95% CI 0.1-0.7, 0-0.8, 0-0.8, and 0-0.8). However, these HLA associations did not remain significant after statistical correction for multiple testing. While anti-Ku myositis shows necrotizing myopathy features, they can be distinguished from anti-SRP/HMGCR IMNM by their MHC class II expression and clusters of perivascular inflammatory cells. The HLA analyses suggest that anti-Ku myositis may have different subsets associated with myopathologic subgroups.


  • Open Access

    Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A

    by Munenori Oyama, Yuko Ohnuki, Akinori Uruha, Yoshihiko Saito, Yukako Nishimori, Shingo Suzuki, Michio Inoue, Jantima Tanboon, Naoko Okiyama, Takashi Shiina, et al.

    Objective: The diagnosis in the studies analyzing HLA of dermatomyositis (DM) was based on a combined clinical category of polymyositis/DM. This retrospective study investigated the associations of HLA with 5 DM-specific autoantibodies in Japanese patients diagnosed by muscle pathology.Methods: We diagnosed Japanese patients with DM based on sarcoplasmic expression of myxovirus resistance protein A. These patients underwent investigation for 5 DM-specific autoantibodies and HLA genotyping.Results: Of 175 patients (83 males and 92 females; range 1-86 yrs; mean 46 yrs), 173 (98.9%) had 1 of the 5 autoantibodies. Seven alleles—A*02:07, B*46:01, DRB1*04:07, DRB1*07:01, DRB1*08:03, DQB1*06:01, andDPB1*02:02—were more frequently detected in the patients with DM than healthy controls, but these associations were not significant after multiple testing correction. Stratifying by DM-specific autoantibodies, we found the associations of 6 already known and 7 new alleles—B*48:01, B*52:01, C*12:02, DRB1*04:05, DRB1*15:02, DPB1*05:01, andDPB1*09:01—with subsets of DM. Moreover, significant associations of 5 alleles with antinucleosome remodeling deacetylase complex (Mi-2) remained after multiple testing correction. In particular, theDRB1*04:07(odds ratio [OR 28.9]; correctedP= 2.7 × 10−6) andDQB1*06:01(OR 4.0; correctedP= 1.6 × 10−4) alleles were significantly more prevalent in patients with anti-Mi-2 antibody than in controls.Conclusion: This study demonstrates DM-specific autoantibodies defined immunogenetic subsets of DM.


  • Association of immune‐mediated necrotizing myopathy withHLApolymorphisms

    by Yuko Ohnuki, Shigeaki Suzuki, Akinori Uruha, Munenori Oyama, Shingo Suzuki, Jerzy K Kulski, Ichizo Nishino, Takashi Shiina

    Immune‐mediated necrotizing myopathy (IMNM) is a type of autoimmune myositis typically characterized clinically by proximal muscle weakness with elevated creatine kinase levels, pathologically by myofiber necrosis and regeneration with paucity of lymphocytic cell infiltration, and serologically by the presence of either of two myositis‐specific autoantibodies, anti‐SRP, and anti‐HMGCR antibodies. However, the HLA loci and alleles associated with IMNM are still not fully understood at least partly because IMNM was a relatively recently established condition. In this study, we genotyped the six HLA loci (HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1 and ‐DPB1) in 250 patients (237 patients over age 18 years and 13 juvenile patients) diagnosed with IMNM based on clinicopathological features and autoantibody information and performed a case control study with Japanese healthy subjects. In the adult patients, specific HLA alleles associated with IMNM were identified at all HLA loci, withDRB1*08:03showing the strongest association (OR = 2.5;p = 0.00000017). Furthermore, subgroup analysis with various clinical information showed thatC*03:04(OR = 3.7;p = 0.00012) was a higher risk allele for collagen disease in adult patients, andB*13:01(OR = 23.2;p = 0.021) andC*03:04(OR = 5.8;p = 0.0074) were higher risk for juvenile patients with anti‐HMGCR antibody‐positive IMNM. These findings will help to better understand the HLA genetic background and features of IMNM in designing future studies.


  • Mild form of Danon disease: two case reports

    by Toshio Yasui, Utako Nagaoka, Yasushi Oya, Akinori Uruha, Jun Karashima, Asuka Funai, Kazuhito Miyamoto, Shiro Matsubara, Keizo Sugaya, Kazushi Takahashi, et al.


  • Updates on the Immunopathology in Idiopathic Inflammatory Myopathies

    by Akinori Uruha, Hans-Hilmar Goebel, Werner Stenzel

    Purpose of Review To review recent advances in immunopathology for idiopathic inflammatory myopathies, focusing on widely available immunohistochemical analyses. Recent Findings Sarcoplasmic expression of myxovirus resistance protein A (MxA) is specifically observed in all types of dermatomyositis and informs that type I interferons are crucially involved in its pathogenesis. It is a more sensitive diagnostic marker than perifascicular atrophy. Diffuse tiny dots in the sarcoplasm highlighted by p62 immunostaining are characteristically seen in immune-mediated necrotizing myopathy. This feature is linked to a chaperone-assisted selective autophagy pathway. Myofiber invasion by highly differentiated T cells, a marker of which is KLRG1, is specific to inclusion body myositis and has a crucial role in its pathogenesis. Summary The recent advances in immunopathology contribute to increased diagnostic accuracy and a better understanding of the underlying pathophysiology in different types of idiopathic inflammatory myopathies.


  • Open Access

    HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis

    by Munenori Oyama, Yuko Ohnuki, Michio Inoue, Akinori Uruha, Satoshi Yamashita, Sachiko Yutani, Jantima Tanboon, Jin Nakahara, Takashi Shiina, Ichizo Nishino, et al.

    Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy, characterized by unique clinical features including finger flexor and quadriceps muscle weakness and a lack of any reliable treatment. The human leukocyte antigen (HLA)-DRB1 allele and autoantibody profiles in Japanese IBM patients have not been fully elucidated. We studied 83 Japanese IBM patients with a mean age of 69 years (49 males and 34 females) who participated in the ‘Integrated Diagnosis Project for Inflammatory Myopathies’ from January 2011 to September 2016. IBM was diagnosed by histological diagnosis. Various autoantibodies were screened by RNA immunoprecipitation and enzyme-linked immunosorbent assays. HLA-DRB1 genotyping was performed using polymerase chain reaction-sequence based typing. A total of 460 unrelated healthy Japanese controls were also studied. The allele frequencies of DRB1*01:01, DRB1*04:10, and DRB1*15:02 were significantly higher in the IBM group than in the healthy control group (Corrected P = 0.00078, 0.00038 and 0.0046). There was a weak association between the DRB1*01:01 allele and severe leg muscle weakness and muscle atrophy. While hepatitis type C virus infection and autoantibodies to cytosolic 5’-nucleotidase 1A were found in 18 and 28 patients, respectively, no significant association with HLA-DRB1 alleles was observed. Japanese IBM patients had the specific HLA-DRB1 allele and autoantibody profiles.